The potential for maintaining the stability of a drug with the convenience of a pre-filled syringe or auto-injector could have a significant impact on reducing the barriers to subcutaneous delivery of therapies and improving the patient experience.
SOMERSET, N.J. and MANGALORE, India (PRWEB)
March 16, 2023
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies.
Under the terms of the agreement, financial details of which have not been disclosed, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products. The technology is applicable to a wide range of monoclonal antibodies and fusion proteins, and successful programs could be integrated into Catalent’s formulation and manufacturing services at scale. Small volume and low viscosity biotherapeutics delivered subcutaneously provide superior patient benefits over traditional intravenous injections including improved access to healthcare, reduced need for hospitalization and overall treatment cost, and the opportunity to employ new delivery technologies such as auto-injectors.
“We are delighted to be expanding the reach of our exciting subcutaneous protein delivery platform to customers through this collaboration with Catalent, a global CDMO of repute,” said Dr. Surya Pai, Co-founder and Chief Executive Officer of BRL. Dr. Bhami Shenoy, Co-founder and Chief Scientific Officer of BRL added, “The patented, high-concentration, low-viscosity protein drug delivery platform has been designed to make patient care convenient, affordable and safe.”
“This agreement allows Catalent Biologics to offer its customers a novel patented formulation that may be evaluated for enabling the delivery of high-concentration therapies by reducing viscosity,” said Julien Meissonnier, Catalent’s Chief Scientific Officer. “The potential for maintaining the stability of a drug with the convenience of a pre-filled syringe or auto-injector could have a significant impact on reducing the barriers to subcutaneous delivery of therapies and improving the patient experience.”
About Bhami Research Laboratory
Bhami Research Laboratory Pvt. Ltd. (BRL) is an eight-year-old biotech based out of India, with core expertise in protein and peptide drug delivery. BRL aims to enhance the delivery of biologics therapeutics through its proprietary high concentration subcutaneous protein delivery technology. Additionally, BRL also focuses on oral delivery of peptides through its novel proprietary technology. For more information, http://www.bhamilab.com.
About Catalent Biologics
For nearly three decades, Catalent Biologics has built capabilities and expertise in development, manufacturing, and analytical services, now spanning new biological entities, biosimilars, plasmid DNA, cell and gene therapies, vaccines, sterile injectables, mRNA, and antibody-drug conjugates. It has developed 600+ antibodies and 80+ recombinant proteins, with more than 120 active clinical trials and 16 marketed biotherapeutics use GPEx® cell line engineering technology. More than 45 commercially approved products have employed Catalent Biologics’ manufacturing and packaging capabilities.
Using advanced technologies and tailored solutions from clinical to commercial supply, Catalent brings better biologic and advanced treatments to patients, faster.
About Catalent
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, http://www.catalent.com
Share article on social media or email: